Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005-2022: an observational study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.China
Area Of Science
- Oncology and Health Economics
- Drug Reimbursement Policies
- Clinical Trial Evidence Evaluation
Background
- China's National Reimbursement Drug List (NRDL) guides public insurance coverage for drugs.
- Assessing cancer drugs' overall survival (OS) benefits is crucial for healthcare resource allocation.
- The evolution of survival evidence post-NRDL inclusion requires examination.
Purpose Of The Study
- To evaluate the overall survival (OS) benefits of cancer drugs included in China's NRDL.
- To analyze the changes in survival evidence for these drugs after NRDL listing.
- To inform reimbursement and disinvestment decisions by assessing clinical benefit evidence.
Main Methods
- Retrospective observational study analyzing adult cancer drug indications in China (2005-2022).
- Data sourced from China's NRDL and journal publications.
- Primary outcome: OS benefit evidence at NRDL listing; Secondary outcome: clinical benefits (OS, ESMO-MCBS) post-listing.
Main Results
- 72.6% of approved cancer indications were NRDL-listed by June 2022.
- The median time from marketing authorization to NRDL inclusion significantly decreased over time (from 9.4 to 1.1 years).
- Only 35.4% of indications had documented OS benefits at NRDL assessment, with a median survival benefit of 3.9 months. 19.3% showed substantial clinical benefit via ESMO-MCBS despite lacking OS data.
Conclusions
- While time to NRDL listing has shortened, over half of listed cancer drugs lack confirmed survival or substantial clinical benefits.
- Payers must prioritize clinical benefit evidence in reimbursement decisions to ensure efficient use of public health funds.
- Further research is needed to optimize drug evaluation and reimbursement strategies for cancer therapies in China.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...